Studienzentrale fuer das MVZ Eggenfelden e.K.

At Studienzentrale fuer das MVZ Eggenfelden e.K., the clinical trial portfolio focuses on oncology, with a strong emphasis on breast cancer across early and advanced disease settings. The studies are exploring new treatment approaches for patients with HER2-positive, hormone receptor-positive, HER2-negative, and triple-negative breast cancer, aiming to improve outcomes and reduce the risk of recurrence.

• Testing new targeted and endocrine-based therapies for PIK3CA-mutant and HR-positive breast cancer
• Evaluating whether adding immunotherapy can improve results in triple-negative breast cancer
• Assessing treatment options for patients with high-risk early breast cancer after standard therapy

Overall, the research at this site is centered on improving treatment effectiveness, extending disease control, and finding better options for patients with different forms of breast cancer.

Several trials at this German clinical research site are dedicated to early breast cancer, especially cases with a higher chance of returning after initial treatment. These studies are examining whether newer therapies can strengthen standard care and provide better protection against disease recurrence in patients with node-positive and estrogen receptor-positive disease.

• Studying new endocrine treatment strategies for early breast cancer with elevated recurrence risk
• Comparing emerging therapies with standard care to improve invasive breast cancer-free survival
• Supporting better long-term disease control after surgery and adjuvant treatment

This research is designed to help identify more effective ways to prevent relapse and improve outcomes for patients living with high-risk breast cancer.

The site is also involved in studies for HER2-positive breast cancer, including patients with residual disease or a high risk of recurrence after standard treatment. These trials are focused on testing whether new immune-based or targeted approaches can add benefit beyond established trastuzumab-based therapy.

• Evaluating a new approach for patients with HER2/neu-positive disease at high risk of recurrence
• Comparing investigational treatment with placebo to measure disease control
• Exploring ways to improve outcomes after completion of standard anti-HER2 treatment

The goal is to refine treatment for HER2-driven breast cancer and improve protection against relapse in patients who still face significant risk after initial therapy.

Research at Studienzentrale fuer das MVZ Eggenfelden e.K. includes trials in locally advanced and metastatic breast cancer, particularly in tumors with PIK3CA mutations and hormone receptor-positive, HER2-negative features. These studies are examining whether newer targeted combinations can better control disease than current endocrine-based treatment options.

• Comparing targeted therapy combinations for PIK3CA-mutant breast cancer
• Assessing disease control in advanced or metastatic settings
• Seeking improved options for patients whose cancer has progressed beyond early-stage disease

This work aims to improve treatment effectiveness in harder-to-treat breast cancer populations and support more personalized care.